Clinical trial · Observational

Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia

Genetic and Epigenetic Determinants of Chemotherapy Resistance and Adverse Outcome in Elderly Patients With AML

NCT01421875CI-TRIAL-00027664completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers related to chemotherapy resistance and outcomes in samples from older patients with acute myeloid leukemia.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Leukemia	Leukemia	ONTOLOGY_EXACT	0.90

Interventions

Interventions (6)

Intervention	Type	Mapped drug	Match
DNA methylation analysis	Genetic	—	UNRESOLVED
gene expression analysis	Genetic	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
microarray analysis	Genetic	—	UNRESOLVED
nucleic acid sequencing	Genetic	—	UNRESOLVED
RNA analysis	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Genetic and epigenetic determinants of chemoresistance and adverse outcomes
timeFrame
1 year

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 61 Years
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Subset of patients diagnosed with acute myeloid leukemia (AML) enrolled on E3999
* AML resistant or sensitive to chemotherapy
* Mononuclear cell samples available

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Aug 17, 2011
Primary completion: Oct 17, 2011
Completion: Oct 17, 2011
First posted: Aug 23, 2011
Last update posted: May 17, 2017
Enrollment: 257 (actual)
Lead sponsor: Eastern Cooperative Oncology Group NETWORK
Collaborators: National Cancer Institute (NCI)
Keywords: adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with del(5q), adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22), untreated adult acute myeloid leukemia, adult acute myeloblastic leukemia without maturation (M1), adult acute myeloblastic leukemia with maturation (M2), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0)

Data updated 22 days agoSource updated May 17, 2017source: clinicaltrials

Locations

Locations by country (0)

No location posted.

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.